Drug General Information
Drug ID
D07LAP
Former ID
DIB009152
Drug Name
BMS-184476
Synonyms
10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 7-O-(Methylsulfanylmethyl)paclitaxel
Drug Type
Small molecular drug
Indication Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] Phase 2 [1]
Structure
Download
2D MOL

3D MOL

Formula
C49H55NO14S
Canonical SMILES
CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC<br />=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(<br />=O)C)OCSC)C)OC(=O)C
InChI
1S/C49H55NO14S/c1-27-33(62-45(57)38(53)37(30-17-11-8-12-18-30)50-43(55)31-19-13-9-14-20-31)24-49(58)42(63-44(56)32-21-15-10-16-22-32)40-47(6,41(54)39(61-28(2)51)36(27)46(49,4)5)34(60-26-65-7)23-35-48(40,25-59-35)64-29(3)52/h8-22,33-35,37-40,42,53,58H,23-26H2,1-7H3,(H,50,55)/t33-,34-,35+,37-,38+,39+,40-,42-,47+,48-,49+/m0/s1
InChIKey
UBJAHGAUPNGZFF-XOVTVWCYSA-N
CAS Number
CAS 160237-25-2
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Tubulin (TUB) Target Info Inhibitor [2], [3]
References
REF 1 Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol. 2005 Apr;16(4):597-601.
REF 2 Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Br J Cancer. 2004 July 19; 91(2): 213-218.
REF 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.